The cardiotoxicity of chemotherapeutic drugs is receiving more and more attention. The incidence and severity of cardiotoxicity can be reduced by methods such as reducing the dose of drugs

adjusting administration

and using low toxic drugs in clinical practice. Besides

appLncation of cardioprotective agents is very important and agents including cardiovascular ones

dexrazoxane as well as Chinese medicine preparations are commonly used currently. However

effects of these agents used for cardioprotection during chemotherapy are limited

and their safety needs further verification.